Search

Raymond J Winquist

from Marshfield, MA
Age ~75

Raymond Winquist Phones & Addresses

  • 196 Carolyn Cir, Marshfield, MA 02050 (781) 834-7542
  • 31 Independence Pl, Chesterbrook, PA 19087 (610) 889-9275
  • 457 Maynard Dr, Strafford, PA 19087 (610) 687-9035 (610) 687-8676
  • Wayne, PA
  • 96 Middlebury Rd, Watertown, CT 06795 (860) 274-5088
  • Ridgefield, CT
  • Chester, PA

Publications

Us Patents

Immunostimulatory Agents In Combination With Angiogenesis Inhibitors

View page
US Patent:
20210347837, Nov 11, 2021
Filed:
Apr 15, 2021
Appl. No.:
17/231309
Inventors:
- Dublin, IE
Heather C. Losey - Lexington MA, US
Raymond J. Winquist - Marshfield MA, US
International Classification:
C07K 14/47
C07K 16/22
A61P 35/00
Abstract:
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).

Immunostimulatory Agents In Combination With Angiogenesis Inhibitors

View page
US Patent:
20210338656, Nov 4, 2021
Filed:
Apr 15, 2021
Appl. No.:
17/231307
Inventors:
- Dublin, IE
- Boulder CO, US
Raymond J. Winquist - Marshfield MA, US
Rachel Dusek - Belmont CA, US
Andrew David Simmons - San Carlos CA, US
International Classification:
A61K 31/47
A61K 38/20
A61P 35/00
Abstract:
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor.

Compositions And Methods For Subcutaneous Administration Of Cancer Immunotherapy

View page
US Patent:
20210052694, Feb 25, 2021
Filed:
Jun 10, 2020
Appl. No.:
16/897920
Inventors:
- Dublin, IE
Jared Lopes - Wilmington MA, US
Lei Sun - Waltham MA, US
Raymond J. Winquist - Marshfield MA, US
International Classification:
A61K 38/16
A61K 9/00
A61P 35/00
C07K 16/28
Abstract:
The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (T) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
Raymond J Winquist from Marshfield, MA, age ~75 Get Report